Actively Recruiting
A Clinical Study for Developing AI-based Clustering Model for Personalized Medicine in Acute Respiratory Failure: Single Center, Prospective Cohort Study
Led by Samsung Medical Center · Updated on 2026-04-28
250
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
S
Samsung Medical Center
Lead Sponsor
M
Ministry of Science and ICT, Republic of Korea
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are conducting a clinical study to develop an artificial intelligence (AI)-based clustering model to personalize medicine for patients with acute respiratory failure who are admitted to the intensive care unit (ICU). The study aims to confirm patient phenotypes and compare clinical characteristics and prognosis between patients requiring advanced oxygen support and a control group without acute respiratory failure. Participants are divided into two groups: those with acute respiratory failure requiring treatment with high flow nasal cannula (HFNC), non-invasive ventilation (NIV), or mechanical ventilation (MV), and a control group who do not need these treatments. Both groups are admitted to the internal medicine ICU at Samsung Seoul Hospital and undergo the same research procedures. During the study, participants' clinical information is collected prospectively for analysis. Researchers will assess hospital mortality up to one year from admission, ICU mortality up to six months, and length of stay in both hospital and ICU. The study involves monitoring patients from admission until discharge or death, with follow-up periods varying up to one year. This observational study is sponsored by Samsung Medical Center.
CONDITIONS
Brief Title
A Clinical Study for Developing Artificial Intelligence(AI)-Based Clustering Model for Personalized Medicine in Acute Respiratory Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older
- For acute respiratory failure group: patients admitted to the internal medicine ICU requiring treatment with high flow nasal cannula, non-invasive ventilation (BIPAP or CPAP), or mechanical ventilation due to acute respiratory failure
- For control group: patients admitted to the internal medicine ICU who do not require treatment with high flow nasal cannula, non-invasive ventilation, or mechanical ventilation and consent to participate
You will not qualify if you...
- Patients who have been receiving oxygen treatment (HFNC, NIV, or MV) for more than 48 hours
- Patients transferred from another hospital
- Patients with limitations in treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From ICU admission until hospital discharge or death, up to 1 year
Participants who are admitted to the intensive care unit are observed to collect data related to acute respiratory failure and treatment outcomes.
Data collected during ICU and hospital stay
Trial Site Locations
Total: 1 location
1
Samsung Medical Center
Seoul, Gangnam, South Korea, 06351
Actively Recruiting
Research Team
R
Ryoung Eun Ko, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here